Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada
Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in CanadaView Video
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

Director/PDMR Shareholding

19 Nov 2009 16:23

RNS Number : 8055C
Plethora Solutions Holdings PLC
19 November 2009
 

PLETHORA SOLUTIONS HOLDINGS PLC

("Plethora" or the "Company")

Directors' dealings

As announced on 18 November 2009, the Directors intend to participate in the Fundraising through the subscription for 1,950,000 new ordinary shares at the placing price of 10p each. In aggregate they will invest £195,000 in the placing, being 12.5% of the Fundraising. The Directors' interests in the Company before and following completion of the Fundraising is set out in the table below.

Number of Ordinary Shares currently held

Number of Ordinary Shares subscribed for

Shares held on Admission of New Ordinary Shares

Options currently held*

Percentage of fully diluted issued share capital

Director

William Robinson

-

1,000,000

1,000,000

-

1.6%

Dr. Steven Powell

4,100

500,000

504,100

1,334,951

2.9%

Dr. Mike Wyllie

486,494

200,000

686,494

724,491

2.3%

Ronald Openshaw

-

250,000

250,000

-

0.4%

*All options held are exercisable at between 59p and 202p

Following the Fundraising, the total enlarged issued share capital of the Company will b41,965,800 and no ordinary shares will be held in treasury. Therefore, following the Placing, the total number of voting rights in the Company will be 41,965,800. The above figure may be used by shareholders in determining whether they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency Rules. 

 

Enquiries:

Plethora Solutions

Steven Powell Tel : +44(0) 20 3077 5400

FinnCap

Geoff Nash/Marc Young Tel : +44(0) 20 7600 1658

Hansard Group

Adam Reynolds/John Bick Tel: +44(0) 20 7245 1100

About Plethora:

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder, stress urinary incontinence, interstitial cystitis, gynaecological pain, erectile dysfunction and premature ejaculation. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:PLE) 

Further information is available at www.plethorasolutions.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSILFFRLLLALIA

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.